FLUTICASONE

Lymphoid Leukemia

Virginia Commonwealth UniversitySmall moleculePhase 2Dormant

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 95/ 100

Competitive context

0 Active assets in the Lymphoid Leukemia cohort.

Asset / Sponsor	Phase	Rating
FILGRASTIM Virginia Commonwealth University	Phase 2	B
Stemex® Gamida Cell -Teva Joint Venture Ltd.	Phase 2/3	B
Cpx-351 H. Lee Moffitt Cancer Center and Research Institute	Phase 2	B
Sargramostim Virginia Commonwealth University	Phase 2	B
Zofran University of Washington	Phase 2	B

View all 11 →

Same molecule, other indications

FLUTICASONE is also rated in:

Unspecified Adult Solid Tumor, Protocol SpecificDormant

BBB

Indicative ·

73 / 100

Recurrent Adult Acute Myeloid LeukemiaDormant

BBB

Indicative ·

73 / 100

Chronic Phase Chronic Myelogenous LeukemiaDormant

BB

Indicative ·

71 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.